Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
03
2020
accepted:
25
07
2020
entrez:
12
8
2020
pubmed:
12
8
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naïve volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholesterol homeostasis (SLC46A1 and LRP1), cancer development (CYP1B1, STAB1, CCR2, TMEM176B), and immune responses (CD14, CD163) after administration of metformin for three months. We demonstrate for the first time a transcriptome-based molecular discrimination between metformin responders (delta HbA1c ≥ 1% or 12.6 mmol/mol) and non-responders (delta HbA1c < 1% or 12.6 mmol/mol), that is determined by expression levels of 56 genes, explaining 13.9% of the variance in the therapeutic efficacy of the drug. Moreover, we found a significant upregulation of IRS2 gene (log2FC 0.89) in responders compared to non-responders before the use of metformin. Finally, we provide evidence for the mitochondrial respiratory complex I as one of the factors related to the high variability of the therapeutic response to metformin in patients with type 2 diabetes mellitus.
Identifiants
pubmed: 32780768
doi: 10.1371/journal.pone.0237400
pii: PONE-D-20-08607
pmc: PMC7418999
doi:
Substances chimiques
Metformin
9100L32L2N
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237400Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diabet Med. 2015 Sep;32(9):1119-20
pubmed: 25962518
J Clin Invest. 2010 Jul;120(7):2355-69
pubmed: 20577053
Lipids Health Dis. 2013 May 08;12:66
pubmed: 23656756
Biochem Biophys Res Commun. 2020 Feb 19;522(4):838-844
pubmed: 31801667
Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):214-222
pubmed: 28862803
Cell Stress Chaperones. 2012 Jan;17(1):23-8
pubmed: 21769504
Sci Rep. 2019 Mar 29;9(1):5369
pubmed: 30926854
J Endocrinol. 2016 May;229(2):133-44
pubmed: 26941037
Front Endocrinol (Lausanne). 2018 Jul 19;9:400
pubmed: 30072954
Genome Biol. 2014 Mar 03;15(3):R47
pubmed: 24580837
Exp Biol Med (Maywood). 2017 Mar;242(6):617-624
pubmed: 28114814
Genomics. 2019 Dec;111(6):1517-1528
pubmed: 30366041
J Clin Invest. 2006 Jan;116(1):101-14
pubmed: 16374520
Oncol Lett. 2018 Jan;15(1):683-690
pubmed: 29422962
PLoS One. 2019 Nov 8;14(11):e0224835
pubmed: 31703101
Biochem J. 2014 Sep 15;462(3):475-87
pubmed: 25017630
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Epidemiol. 2018 Aug 5;28(8):353-360
pubmed: 29576601
Hormones (Athens). 2019 Jun;18(2):141-144
pubmed: 30719628
Biochim Biophys Acta Mol Basis Dis. 2017 Aug;1863(8):1984-1990
pubmed: 27702625
Toxicol Appl Pharmacol. 2014 Oct 1;280(1):138-48
pubmed: 25110054
Diabetes Metab. 2003 Jun;29(3):279-83
pubmed: 12909816
Ther Adv Endocrinol Metab. 2010 Jun;1(3):117-28
pubmed: 23148156
PLoS Genet. 2016 Nov 30;12(11):e1006449
pubmed: 27902686
Nucleic Acids Res. 2014 Jun;42(11):e91
pubmed: 24753412
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cancer Sci. 2019 Apr;110(4):1256-1267
pubmed: 30689265
Diabetes. 2008 Sep;57(9):2296-303
pubmed: 18544705
Acta Histochem. 2012 Nov;114(7):705-12
pubmed: 22244448
Curr Drug Targets. 2012 Dec;13(13):1603-15
pubmed: 22998183
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Cancer Cell. 2019 May 13;35(5):767-781.e6
pubmed: 31085177
Drug Discov Today. 2015 May;20(5):505-13
pubmed: 25582842
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):546-51
pubmed: 27366724
J Diabetes Res. 2017;2017:6549242
pubmed: 29445750
Sci Rep. 2018 Feb 27;8(1):3747
pubmed: 29487289
Liver Int. 2012 Aug;32(7):1064-78
pubmed: 22583549
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
PLoS One. 2016 Mar 15;11(3):e0151543
pubmed: 26978661
J Hum Genet. 2007;52(2):117-122
pubmed: 17111267
Cancer Metab. 2014 Aug 28;2:12
pubmed: 25184038
EBioMedicine. 2019 Jan;39:591-602
pubmed: 30553752
J Clin Pharmacol. 1996 Nov;36(11):1012-21
pubmed: 8973990
BMB Rep. 2013 Apr;46(4):181-7
pubmed: 23615258
Oncotarget. 2015 Nov 3;6(34):36441-55
pubmed: 26497364
J Clin Endocrinol Metab. 2003 Mar;88(3):1323-32
pubmed: 12629126
F1000Res. 2016 Jun 17;5:1408
pubmed: 27441086
Oncotarget. 2017 Apr 18;8(16):27199-27215
pubmed: 28423712
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Diabetes. 2014 Mar;63(3):880-91
pubmed: 24270984
Diabet Med. 2007 Apr;24(4):350-8
pubmed: 17335466
Am J Med. 1997 Dec;103(6):491-7
pubmed: 9428832
Pak J Med Sci. 2019 Jan-Feb;35(1):71-76
pubmed: 30881399
PLoS One. 2018 Sep 27;13(9):e0204317
pubmed: 30261008
Mol Ther Nucleic Acids. 2015 Nov 03;4:e262
pubmed: 26528939